Highly active antiretroviral therapy
New research on immune system diseases and conditions reveals that antiretroviral treatments have varying efficacy and safety profiles in patients with late diagnosis of HIV/AIDS. The study, conducted in Berlin, Germany, compared the outcomes of patients starting first-line antiretroviral treatment (ART) with either dolutegravir/lamivudine (DTG/3TC) or bictegravir/
HIV patients
A new study conducted by researchers from the University of Copenhagen and the Centre of Excellence for Health, Immunity Infections (CHIP) has found an association between the use of raltegravir, an integrase strand-transfer inhibitor (INSTI), and higher mortality rates in HIV patients. The study, published in eClinicalMedicine, analyzed data from
HIV patients
Research findings presented in a new study published in Comprehensive Psychiatry have revealed that HIV-associated neurocognitive disorders (HAND) remain a significant public health concern among people living with HIV (PWH) in Africa, even with the widespread implementation of highly active antiretroviral therapy (HAART). The study, conducted by researchers from the
HIV patients
A recent study published in the Journal of Lipids in Health and Disease has found that the use of cotrimoxazole is associated with lower total and non-high-density lipoprotein (HDL) cholesterol levels in people with HIV. The research, conducted by a team of researchers at the Division of Pulmonology, Kiruddu National
Dolutegravir
A team of investigators from Federal University Bahia conducted a comprehensive study on the clinical outcomes of dolutegravir (DTG) treatment in people living with HIV in Brazil. The research, known as the Clinical Outcomes of Dolutegravir Treatment in People Living with HIV in Brazil (CODE) cohort study, aims to assess
B cells
A study published in Frontiers in Immunology has uncovered the complex immune cell architecture responsible for HIV control in a subset of individuals known as HIV controllers. Researchers from Radboud University Medical Center in Nijmegen, Netherlands, analyzed immune cells from 54 HIV controllers, including 21 elite controllers, and compared them
Drug resistance
Researchers at the University of Campania 'Luigi Vanvitelli' in Naples, Italy, have made a significant breakthrough in HIV/AIDS treatment by exploring new combination therapies. Despite the progress of antiretroviral therapy, some patients with multidrug-resistant (MDR) HIV infection continue to struggle with the disease. The study investigated the
Highly active antiretroviral therapy
Research has shown that disrupting services provided by the Ryan White HIV/AIDS Program could lead to a significant increase in HIV infections in the United States. According to a study published in the Annals of Internal Medicine in 2025, ending Ryan White services in July 2025 could result in
Highly active antiretroviral therapy
The Gates Foundation has partnered with Hetero, a global leader in APIs and generic drug manufacturing, to supply a generic version of lenacapavir for HIV prevention. This collaboration aims to make a low-cost, twice-yearly injectable PrEP therapy accessible to millions of people at risk of HIV in low- and middle-income
Highly active antiretroviral therapy
Researchers at the University of Kinshasa have conducted a study to describe the lipid profile of people living with HIV (PLHIV) on antiretroviral therapy in a hospital setting in Kinshasa, the Democratic Republic of the Congo. The study, published in the Orapuh Journal, found that despite the beneficial effects of
Evidence-based medicine
Research by the Mid-Atlantic Permanente Research Institute has highlighted the significant progress made in antiretroviral therapy (ART) for individuals with human immunodeficiency virus (HIV), enabling them to live a lifespan approaching that of people without HIV. This has led to an increased emphasis on maintaining health throughout the lifespan, with
Georgia Southern University
A new study has identified significant challenges faced by patients living with HIV (PLHIV) in the Democratic Republic of Congo, resulting in missed clinical care and impacting their health outcomes. The research, conducted by Georgia Southern University, analyzed data from 5338 adults living with HIV who received antiretroviral treatment (ART)
